Trelagliptin Impurities

Trelagliptin is used to:

• Improve glycemic control in adults with type 2 diabetes mellitus (T2DM).
• Enhance insulin secretion and reduce glucagon levels after meals.
• Provide convenience with its once-weekly dosing
• May be used alone or in combination with other oral antidiabetic drugs like metformin or sulfonylureas.

Trelagliptin is not indicated for type 1 diabetes or diabetic ketoacidosis.

• No, Trelagliptin is not FDA approved.
• It was approved in Japan under the brand name Zafatek but has not received approval from the S. FDA or European Medicines Agency (EMA).
• Its use is currently limited to Japan and some Asian markets.

• Yes, Trelagliptin has been shown to significantly reduce HbA1c levels in patients with type 2 diabetes.
• Clinical trials demonstrated an average reduction of 0.5% to 1.0% in HbA1c levels after 12 to 24 weeks of treatment.
• Effectiveness is comparable to other DPP-4 inhibitors like sitagliptin and linagliptin.

• Zafatek – The main brand name for Trelagliptin in Japan.
• Not available in the U.S. or Europe due to lack of FDA or EMA approval.
• Manufactured by Takeda Pharmaceutical Company.